Research output: Contribution to Journal/Magazine › Journal article › peer-review
Influenza vaccination for immunocompromised patients : systematic review and meta-analysis by etiology. / Beck, Charles R.; McKenzie, Bruce C.; Hashim, Ahmed B. et al.
In: The Journal of infectious diseases, Vol. 206, No. 8, 2012, p. 1250-1259.Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Influenza vaccination for immunocompromised patients
T2 - systematic review and meta-analysis by etiology
AU - Beck, Charles R.
AU - McKenzie, Bruce C.
AU - Hashim, Ahmed B.
AU - Harris, Rebecca C.
AU - Nguyen-Van-Tam, Jonathan S.
AU - University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group,
AU - Isba, Rachel
PY - 2012
Y1 - 2012
N2 - Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and meta-analyses to assess the evidence for influenza vaccination in this group, and we report our results by etiology. Meta-analyses showed significantly lower odds of influenza-like illness after vaccination in patients with human immunodeficiency virus (HIV) infection, patients with cancer, and transplant recipients and of laboratory-confirmed influenza in HIV-positive patients, compared with patients receiving placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive patients, patients with cancer, and transplant recipients, compared with immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between etiological groups. Limited evidence of a transient increase in viremia and a decrease in the percentage of CD4(+) cells in HIV-positive patients was found although not accompanied by worsening of clinical symptoms. Clinical judgment remains important when discussing the benefits and safety profile with immunocompromised patients.
AB - Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and meta-analyses to assess the evidence for influenza vaccination in this group, and we report our results by etiology. Meta-analyses showed significantly lower odds of influenza-like illness after vaccination in patients with human immunodeficiency virus (HIV) infection, patients with cancer, and transplant recipients and of laboratory-confirmed influenza in HIV-positive patients, compared with patients receiving placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive patients, patients with cancer, and transplant recipients, compared with immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between etiological groups. Limited evidence of a transient increase in viremia and a decrease in the percentage of CD4(+) cells in HIV-positive patients was found although not accompanied by worsening of clinical symptoms. Clinical judgment remains important when discussing the benefits and safety profile with immunocompromised patients.
U2 - 10.1093/infdis/jis487
DO - 10.1093/infdis/jis487
M3 - Journal article
C2 - 22904335
VL - 206
SP - 1250
EP - 1259
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 8
ER -